Systemic Lupus Clinical Trial
Official title:
Improvement of Medication Adherence in Adolescents With SLE Using Web-based Education With and Without a Social Media Intervention
The goal of this study was to examine the effect of an online educational program with and without a social media experience.The primary goal of this study was to determine whether medication adherence would be improved by having adolescents and young adults with systemic lupus erythematosus participate in an online educational website, with or without a social media experience. The secondary goal was to determine whether secondary outcomes such as quality of life, stress, and self-efficacy improved in this model, and whether these changes were associated with improvements in medication management.
Self-management skills, including medication management, are vital to the health of
adolescents and young adults with systemic lupus erythematosus (SLE). Non-adherence with
medications in patients with systemic lupus has been noted to be as poor as 40%. Success in
disease control can be significantly impacted by such non-adherence. Poor medication
compliance is associated with higher SLE disease activity scores and higher SLE disease
activity in turn has been demonstrated to be significantly associated with a decline in
quality of life. Much attention has been paid to how to improve self-management skills in
adults, but less is known about how to target adolescents, an age group with a complex set of
emotional and developmental needs.
The goal of this study was to examine the effect of an online educational program with and
without a social media experience.The primary goal of this study was to determine whether
medication adherence would be improved by having adolescents and young adults with SLE
participate in an online educational website, with or without a social media experience. The
secondary goal was to determine whether secondary outcomes such as quality of life, stress,
and self-efficacy improved in this model, and whether these changes were associated with
improvements in medication management.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03749044 -
ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies
|
N/A | |
| Not yet recruiting |
NCT03752983 -
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
|
||
| Recruiting |
NCT03819777 -
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
|
||
| Recruiting |
NCT04894253 -
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
|
||
| Not yet recruiting |
NCT03164720 -
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
|
||
| Completed |
NCT03762824 -
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
|
Phase 4 | |
| Not yet recruiting |
NCT06435468 -
Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases
|
N/A | |
| Terminated |
NCT01738360 -
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
|
Phase 2 | |
| Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
| Completed |
NCT04108611 -
Immune Adsorption Role in Treatment of Resistant Lupus
|
N/A | |
| Not yet recruiting |
NCT04256577 -
Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
|
||
| Completed |
NCT03540823 -
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
|
Phase 4 |